Abstract: Methods and compounds for use in promoting survival of at least one eukaryotic cell, wherein the compounds are effective as gamma-ketoaldehyde scavengers.
Abstract: The present disclosure provides methods of treating lymphoid malignancies such as B cell malignancies using a BTK inhibitor in the described therapeutic regimens.
Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.
Type:
Grant
Filed:
July 21, 2020
Date of Patent:
April 4, 2023
Assignees:
Universite de Paris, Assistance Publique—Hopitaux de Paris
Inventors:
Nicolas Dupin, Vincent Calvez, Philippe Grange, Anne-Geneviève Marcelin
Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.
Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
Type:
Grant
Filed:
April 1, 2022
Date of Patent:
March 21, 2023
Assignee:
AbbVie Inc.
Inventors:
Ana Paula Machado De Lacerda, Jose Jeffrey V. Enejosa, Aileen L. Pangan, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Wen Zhou
Abstract: A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula at least one acidifying agent; and a vehicle base comprising at least one pharmaceutically acceptable non-aqueous solvent. Values and preferred values of the variables in structural formula (I) are defined herein.
Abstract: An emulsifiable concentrate may include: an aminoindane amide having the structure of formula (I); and an amide having the structure of formula (II); wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, R13, and n are as defined herein, as well as to formulations containing the same, and to methods of their preparation and use for treatment and protection of agricultural crops.
Type:
Grant
Filed:
December 13, 2018
Date of Patent:
March 7, 2023
Inventors:
Robbie Moss Haines, Charlie James Flood, Hong Zhang, David Bird, Laibin B. Yan, Frank J. Zawacki, Claudio Dacarro, Elisa Galimberti, Ilenia Mazzali
Abstract: This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Abstract: Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.
Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
Type:
Grant
Filed:
April 28, 2022
Date of Patent:
January 31, 2023
Assignee:
AbbVie Inc.
Inventors:
Aileen L. Pangan, Roopal B. Thakkar, Steven Jungerwirth, Ana Paula Machado De Lacerda, Anne M. Robinson, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Wen Zhou
Abstract: The invention provides 2-(substituted phenylhetero) aromatic formate FTO inhibitors, a preparation method thereof, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted phenylhetero) aromatic formate compound represented by the following formula (I), and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, which can be used as an FTO targeting inhibitor for treating diseases associated with FTO targets, including obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's diseases, and cancers such as breast cancers, small-cell lung cancers, human bone marrow rhabdomyosarcoma, pancreatic cancer, malignant glioblastoma and the like.
Type:
Grant
Filed:
March 1, 2018
Date of Patent:
January 17, 2023
Assignee:
SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventors:
Caiguang Yang, Yue Huang, Ze Dong, Tao Zhang, Hongjiao Xu
Abstract: The disclosure relates to uses, methods and compositions for the inactivation of pathogens in biological compositions, using a glycol as a pathogen inactivating agent.
Type:
Grant
Filed:
December 23, 2011
Date of Patent:
January 17, 2023
Assignee:
Laboratoire Français du Fractionnement et des Biotechnologies
Abstract: The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compounds have the formula: [Chem.
Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
Type:
Grant
Filed:
September 22, 2016
Date of Patent:
January 3, 2023
Assignee:
Janssen Pharmaceutica NV
Inventors:
Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
Abstract: The present disclosure is directed to method of treatment for treating or ameliorating various conditions caused by radiation exposure such as RIGS, enteritis, mucositis, e.g., oral mucositis, and proctitis by the administration of compound 512, or an analog thereof.
Abstract: The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, F or OH; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.
Abstract: A method for treating psoriasis including the steps of applying an isothiocyanate functional surfactant to an area affected by psoriasis, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
Abstract: This invention pertains to an anti-microbial, in particular anti-bacterial, more particularly against Gram negative bacteria, and/or anti-fungal composition comprising as active blend trans-cinnamaldehyde and a potentiating agent. In particular this composition is intended for preventing and/or treating microbial infection in an animal.